Kelun-Biotech to Present Clinical Study Results at ESMO Congress

What's Happening?

Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, is set to present results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany. The company will showcase data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT), HER2 ADC A166, and CLDN18.2 ADC SKB315. Notably, two Phase III clinical studies of sac-TMT have been selected for the Latest Breakthrough Abstracts and will be presented as oral reports, including one featured in the Presidential Symposium. Kelun-Biotech focuses on innovative biological drugs and small molecule drugs, targeting major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases.

Why It's Important?

The presentation of these clinical study results is significant as it highlights Kelun-Biotech's advancements in the field of antibody-drug conjugates (ADCs), which are crucial in cancer treatment. The company's focus on innovative drugs addresses unmet medical needs, potentially offering new treatment options for patients with various types of cancer. The selection of their studies for the Latest Breakthrough Abstracts underscores the potential impact of their research on the global oncology community. This development could enhance Kelun-Biotech's position as a leading enterprise in innovative drug development.

What's Next?

Kelun-Biotech is expected to continue its research and development efforts, with ongoing clinical studies and potential new drug applications. The company has initiated several registrational clinical studies in China and is collaborating globally to advance its ADC projects. The outcomes of these studies could lead to new treatment approvals and expanded market presence, further solidifying Kelun-Biotech's role in addressing global cancer treatment needs.